There is plenty of good news to support the 30% move made by Baxter (NYSE:BAX) shares in the past year. The company's dividend has risen 44% in that time frame. Sales, earnings, and cash flow notched record highs in 2012, which enabled the company to make $1.2 billion in capital investments and spend $2.3 billion on dividends and share repurchases. Last year also marked at least five straight years of growing dividend payments and revenue. Not too bad.
Most of the success can be attributed to management's focus on optimizing operations, which include dropping its generic injectables business, shoring up pension obligations, and consolidating departments. It seems to be paying off; but can Baxter's two business segments -- BioScience and Medical Products -- keep shares on an upward path?
Unlike several competitors, the company's Medical Products segment isn't overexposed to low-margin medical devices. Instead, Baxter offers intravenous solutions, premixed drugs, pre-filled vials and syringes, anesthetics, drug packaging services, and infusion pumps. That doesn't mean it gets to ditch the risk, though.
A costly recall of Colleague infusion pumps that forced the company to take a $588 million charge to net income in 2010 -- and tens of millions more in other years -- is now finally behind it. It isn't alone. Johnson & Johnson (NYSE:JNJ) and Stryker (NYSE:SYK) both suffered setbacks with hip implants in recent years, although few companies have a recall history that rivals Johnson & Johnson.
While they are hardly the only companies facing problems with medical devices, I believe all three present favorable risk-reward ratios for investors. Stryker has been a pretty reliable growth stock for long-term investors over the years. Despite some recent rough patches, the company has grown revenue from $6.72 billion in 2009 to $8.66 billion in 2012. Income has been the only sore spot for investors, which has greatly lagged the growth in sales. Perhaps that is the reason shares are barely keeping up with the S&P 500.
Luckily for Baxter and Johnson & Johnson, each has the luxury of a pharmaceutical business to make it through choppy seas in the medical device industry. The latter has an impressive array of next-generation biologics on the market for various indications. Remicade, Stelara, and Simponi raked in $7.7 billion for the company in 2012 -- 17% more than 2011 sales. Procrit, which encourages red blood cell creation, brought in $1.4 billion despite slowing sales. Can Baxter achieve similar success?
Medical Products is important to the top and bottom line, but BioScience is what I believe will fuel future growth for shareholders. That is a relatively easy prediction to make, especially given that Baxter had six products approved by global regulatory agencies in 2012. Among them was Gammagard Liquid that, despite failing a phase 3 Alzheimer's trial in May, became the first immunoglobin treatment approved for multifocal motor neuropathy in the United States.
The treatment will add to its quickly growing expertise in blood treatments and biologics. Speaking of which, Baxter and Halozyme (NASDAQ:HALO) had HyQvia approved for marketing in Europe earlier this year. The therapy boosts the immune systems of patients with primary and secondary immunodeficiencies, and combines multiple therapies -- both intravenous and subcutaneous -- into one subcutaneous product. It also allows patients to administer treatment at home every three to four weeks. In other words, it knocks the convenience category out of the park. Halozyme has had a tumultuous life on the public market, so this could be just the stabilizer shareholders need.
The only other treatment in late-stage development is a phase 3 trial for autologous stem cells being evaluated for patients with heart disease. I don't see this having a successful outcome, much like the Gammagard Liquid trial for Alzheimer's. The medical community doesn't fully understand Alzheimer's, or how best to utilize stem cells in a controlled treatment, although using autologous (coming from the patient) stem cells may be analogous to plasma-enrichment therapy -- something that does, in fact, work. The bad news is that it may not work. The good news is that Baxter can afford to take risks. The great news is that the rewards could be tremendous.
Foolish bottom line
Baxter is smaller than Johnson & Johnson, more diverse than Stryker, and operating at optimal efficiency. It may not have the stellar biologic drugs of Johnson & Johnson, but it is carving out a nice niche for itself in the biologic arena. I cannot guarantee that shares won't cool off a little bit from recent highs. However, with a dividend near 3%, and a P/E under 17, there isn't much long-term investors can complain about.
Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.
The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.